Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity
about
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiesIsolation and characterization of human apolipoprotein M-containing lipoproteinsStructure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymesParaoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicityThe human paraoxonase gene cluster as a target in the treatment of atherosclerosisCaenorhabditis elegans paraoxonase-like proteins control the functional expression of DEG/ENaC mechanosensory proteins.Human PON1, a biomarker of risk of disease and exposureThe plasma membrane of bloodstream-form African trypanosomes confers susceptibility and specificity to killing by hydrophobic peptidesIn vivo administration of BL-3050: highly stable engineered PON1-HDL complexesParaoxonase 1 activity and phenotype distribution in premenopausal and postmenopausal women.Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairmentA retained secretory signal peptide mediates high density lipoprotein (HDL) assembly and function of haptoglobin-related protein.Paraoxonase gene mutations in amyotrophic lateral sclerosis.Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice.Species differences in paraoxonase mediated hydrolysis of several organophosphorus insecticide metabolites.Uncleaved ApoM signal peptide is required for formation of large ApoM/sphingosine 1-phosphate (S1P)-enriched HDL particles.Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis.In vitro detoxification of cyclosarin in human blood pre-incubated ex vivo with recombinant serum paraoxonases.p.Q192R SNP of PON1 seems not to be Associated with Carotid Atherosclerosis Risk Factors in an Asymptomatic and Normolipidemic Brazilian Population Sample.Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability.Apolipoprotein M: progress in understanding its regulation and metabolic functions.Human paraoxonase 1 hydrolysis of nanomolar chlorpyrifos-oxon concentrations is unaffected by phenotype or Q192R genotype.Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression.Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds.Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemiaComputational Modeling of Human Paraoxonase 1: Preparation of Protein Models, Binding Studies, and Mechanistic Insights.Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners?Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.Active Site Hydrophobicity and the Convergent Evolution of Paraoxonase Activity in Structurally Divergent Enzymes: The Case of Serum Paraoxonase 1.Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity.Paraoxonase 1 in chronic kidney failureAntioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases.Signal peptides: new markers in cardiovascular disease?Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels.Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.Speciated High-Density Lipoprotein Biogenesis and Functionality.HDL3 stimulates paraoxonase 1 antiatherogenic catalytic and biological activities in a macrophage model system: in vivo and in vitro studies.Humoral mechanisms of atherogenesis.
P2860
Q24298200-364DFD82-DAD8-42F6-BBD6-2AF98CC754B7Q24336276-17B3B668-4ED8-490E-9046-8E12F68C2E69Q24337370-0735A379-064F-4741-B7F0-C0518C2047D9Q24602455-B79749F1-C78D-4AC1-BF80-CCB265990736Q26824356-ADE4715B-3567-4D46-8A5E-7AF159364718Q27305177-DFEB93BD-F14F-4987-9FCC-A67FD08EF2A8Q28386131-FB1D090E-2745-4B60-B27B-DCA98E98265FQ30496567-1471E849-7C78-4700-88BF-F65F834B8263Q30891417-E2773758-90BE-40F3-8853-486DD0955760Q33852109-505E7CD1-6B6E-49DA-89D3-E81E2A5E22D8Q33878870-BD26243B-1C6D-4D0E-9D09-C9E706B6FC9DQ34138923-4CA9906D-B4C3-45C5-AAA9-EBAFE51B481EQ34155982-F3FE27DB-D4CC-4682-A5B7-145507C2ED64Q34546651-D744DD74-8FB9-4935-803E-ADD0BD2E9BB6Q35133061-920517E4-A72F-4631-8DB0-7A4464D5C3EFQ35199447-C214676D-9133-4EBC-877F-84FD61389D40Q35216322-E5DD1CC7-0225-4D98-85D8-EBAB1C2DA261Q35308275-946AD51C-57BC-494B-9209-E364F9D7306AQ35911628-31D29BA2-E484-4C0C-8DF0-459AFD3C9F0CQ36503047-C1245B2D-87B9-44B5-8477-09A33A936B38Q36564408-22775376-8037-4822-9984-E311B0EA9003Q36652565-CA269A8C-CE39-4259-81B3-F7EB04F0CA1BQ36755360-B0C16893-5009-4676-9603-541670F72164Q36756048-2D2F0B02-B601-4F11-8DD0-D1C70D48575EQ36971490-FFEA2167-D8FC-4D5C-9E17-F9614A4DC064Q37015961-7ECF5232-1E76-4A2A-9EBE-ACC0F854A746Q37198237-793066D6-FEB7-4FFC-AC7E-65DE6C7DA5ADQ37291848-E47E3F6F-A7E9-4AB3-8584-42541E2CFF1DQ37318783-4841C035-2444-4701-BBD8-D04F2BAAAD57Q37463147-82344858-067C-415A-849F-691360DD5D6CQ37609374-C1F0A461-6398-40BE-BC7D-EB754ED143D7Q37698417-0D787D5E-0B81-4D46-A347-32429EE4830DQ38004498-25882731-218E-4927-BF5C-B2C7D40747A0Q38062539-3F1614DB-96E1-40B7-87ED-9123288336B4Q38262570-96439808-C1AF-45F2-98B2-F5AF5DD6F122Q38348866-415AEF88-B0BE-42FD-8436-6F5D5F44281AQ38384208-75FE618A-B28E-4A9D-B697-24E875DA512FQ38785650-DB7F46F1-A78E-4E8F-A87E-33C909B6741EQ38955607-3FAF1A95-7140-4A0D-B141-9429F9273BDFQ39946768-68ED59BE-8B8D-4819-A8B3-BF7BE4161C5C
P2860
Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@ast
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@en
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@en-gb
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@nl
type
label
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@ast
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@en
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@en-gb
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@nl
prefLabel
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@ast
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@en
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@en-gb
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@nl
P2093
P356
P1476
Human serum Paraoxonase/Aryles ...... rotein A-I stabilizes activity
@en
P2093
P304
P356
10.1161/01.ATV.19.9.2214
P407
P577
1999-09-01T00:00:00Z